{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:49:12Z","timestamp":1777103352172,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA225647"],"award-info":[{"award-number":["R01 CA225647"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40273-021-01071-0","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T01:02:44Z","timestamp":1628643764000},"page":"1271-1297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Systematic\u00a0Review of Economic and Quality-of-Life Research in Carcinoid Syndrome"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2781-2629","authenticated-orcid":false,"given":"I-Wen","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3113-930X","authenticated-orcid":false,"given":"Daniel M.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8884-1071","authenticated-orcid":false,"given":"Bumyang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James C.","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7290-3864","authenticated-orcid":false,"given":"Ya-Chen Tina","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,11]]},"reference":[{"issue":"4","key":"1071_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","volume":"18","author":"DM Halperin","year":"2017","unstructured":"Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525\u201334.","journal-title":"Lancet Oncol"},{"key":"1071_CR2","unstructured":"NCCN guidelines for patients\u2014neuroendocrine tumors. Plymouth Meeting, PA: National Comprehensive Cancer Network (NCCN); 2018"},{"issue":"3","key":"1071_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","volume":"41","author":"JL Beaumont","year":"2012","unstructured":"Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012;41(3):461\u20136.","journal-title":"Pancreas"},{"key":"1071_CR4","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) neuroendocrine and adrenal tumors. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2019"},{"issue":"8","key":"1071_CR5","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1097\/MPA.0000000000001384","volume":"48","author":"BG Naraev","year":"2019","unstructured":"Naraev BG, Halland M, Halperin DM, Purvis AJ, O\u2019Dorisio TM, Halfdanarson TR. Management of diarrhea in patients with carcinoid syndrome. Pancreas. 2019;48(8):961\u201372.","journal-title":"Pancreas"},{"key":"1071_CR6","unstructured":"Sandostain LAR Depot (octreotide acetate for injectable suspension). US Food and Drug Administration; 1998"},{"issue":"7","key":"1071_CR7","first-page":"424","volume":"44","author":"R Cook","year":"2019","unstructured":"Cook R, Hendifar AE. Evidence-based policy in practice: management of carcinoid syndrome diarrhea. P T. 2019;44(7):424\u20137.","journal-title":"P T"},{"issue":"9","key":"1071_CR8","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1634\/theoncologist.2014-0120","volume":"19","author":"JR Strosberg","year":"2014","unstructured":"Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014;19(9):930\u20136.","journal-title":"Oncologist"},{"issue":"6","key":"1071_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1159\/000499049","volume":"96","author":"EM Wolin","year":"2019","unstructured":"Wolin EM, Benson Iii AB. Systemic treatment options for carcinoid syndrome: a systematic review. Oncology. 2019;96(6):273\u201389.","journal-title":"Oncology"},{"issue":"2","key":"1071_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)\u2014explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231\u201350.","journal-title":"Value Health."},{"issue":"10","key":"1071_CR11","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1007\/s11136-019-02214-9","volume":"28","author":"K Haraldstad","year":"2019","unstructured":"Haraldstad K, Wahl A, Andenaes R, Andersen JR, Andersen MH, Beisland E, et al. A systematic review of quality of life research in medicine and health sciences. Qual Life Res. 2019;28(10):2641\u201350.","journal-title":"Qual Life Res"},{"issue":"8","key":"1071_CR12","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jama.1994.03520080061045","volume":"272","author":"TM Gill","year":"1994","unstructured":"Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA. 1994;272(8):619\u201326.","journal-title":"JAMA"},{"key":"1071_CR13","unstructured":"Consumer Price Index\u2014Medical Care Component. CPI for all urban consumers. Washington: US Bureau of Labor Statistics; 2021"},{"key":"1071_CR14","unstructured":"International Monetary Fund. World Economic Outlook database. Octobor, 2019 edn: International Monetary Fund; 2019"},{"issue":"7","key":"1071_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7): e1000097.","journal-title":"PLoS Med"},{"issue":"6","key":"1071_CR16","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.3748\/wjg.v22.i6.2118","volume":"22","author":"MS Broder","year":"2016","unstructured":"Broder MS, Chang E, Romanus D, Cherepanov D, Neary MP. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome. World J Gastroenterol. 2016;22(6):2118\u201325.","journal-title":"World J Gastroenterol"},{"issue":"23","key":"1071_CR17","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.2217\/fon-2018-0129","volume":"14","author":"T Burton","year":"2018","unstructured":"Burton T, Lapuerta P. Economic analysis of inadequate symptom control in carcinoid syndrome in the United States. Fut Oncol. 2018;14(23):2361\u201370.","journal-title":"Fut Oncol."},{"issue":"47","key":"1071_CR18","doi-asserted-by":"publisher","first-page":"6857","DOI":"10.3748\/wjg.v25.i47.6857","volume":"25","author":"A Dasari","year":"2019","unstructured":"Dasari A, Joish VN, Perez-Olle R, Dharba S, Balaji K, Halperin DM. Direct costs of carcinoid syndrome diarrhea among adults in the United States. World J Gastroenterol. 2019;25(47):6857\u201365.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"1071_CR19","first-page":"507","volume":"20","author":"A Dasari","year":"2020","unstructured":"Dasari A, Joish VN, Perez-Olle R, Dharba S, Balaji K, Halperin DM. Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. Expert Rev. 2020;20(5):507\u201311.","journal-title":"Expert Rev"},{"issue":"9","key":"1071_CR20","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1097\/MPA.0000000000001403","volume":"48","author":"L Huynh","year":"2019","unstructured":"Huynh L, Cai BL, Cheng M, Lax A, Lejeune D, Duh MS, et al. Analysis of real-world treatment patterns, healthcare resource utilization, and costs between octreotide and lanreotide among patients with neuroendocrine tumors. Pancreas. 2019;48(9):1126\u201335.","journal-title":"Pancreas"},{"issue":"9","key":"1071_CR21","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/13696998.2017.1337019","volume":"20","author":"L Huynh","year":"2017","unstructured":"Huynh L, Totev T, Vekeman F, Neary MP, Duh MS, Benson AB. Cost reduction from resolution\/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR. J Med Econ. 2017;20(9):945\u201351.","journal-title":"J Med Econ"},{"issue":"12","key":"1071_CR22","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1080\/00365521.2018.1531653","volume":"53","author":"E Lesen","year":"2018","unstructured":"Lesen E, Bjorstad A, Bjorholt I, Marlow T, Bollano E, Feuilly M, et al. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study. Scand J Gastroenterol. 2018;53(12):1509\u201318.","journal-title":"Scand J Gastroenterol"},{"issue":"12","key":"1071_CR23","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1634\/theoncologist.2017-0149","volume":"22","author":"C Shen","year":"2017","unstructured":"Shen C, Chu Y, Halperin DM, Dasari A, Zhou S, Xu Y, et al. Carcinoid syndrome and costs of care during the first year after diagnosis of neuroendocrine tumors among elderly patients. Oncologist. 2017;22(12):1451\u201362.","journal-title":"Oncologist"},{"issue":"6","key":"1071_CR24","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40273-020-00896-5","volume":"38","author":"K Fust","year":"2020","unstructured":"Fust K, Maschio M, Kohli M, Singh S, Pritchard DM, Marteau F, et al. A budget impact model of the addition of telotristat ethyl treatment to the standard of care in patients with uncontrolled carcinoid syndrome. Pharmacoeconomics. 2020;38(6):607\u201318.","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"1071_CR25","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.clinthera.2017.10.019","volume":"39","author":"VN Joish","year":"2017","unstructured":"Joish VN, Frech F, Lapuerta P. Budgetary impact of telotristat ethyl, a novel treatment for patients with carcinoid syndrome diarrhea: a US health plan perspective. Clin Ther. 2017;39(12):2338\u201344.","journal-title":"Clin Ther"},{"issue":"2","key":"1071_CR26","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/13696998.2017.1387120","volume":"21","author":"VN Joish","year":"2018","unstructured":"Joish VN, Frech F, Lapuerta P. Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs. J Med Econ. 2018;21(2):182\u20138.","journal-title":"J Med Econ"},{"key":"1071_CR27","unstructured":"Pharmacoeconomic Review Report: Telotristat Ethyl (Xermelo): (Ipsen Biopharmaceuticals Canada Inc): Indication: refractory carcinoid syndrome diarrhea, in combination with somatostatin analogue (SSA) therapy, in patients inadequately controlled by SSA therapy alone. Ottawa (ON), 2019"},{"key":"1071_CR28","first-page":"335","volume":"10","author":"K Blot","year":"2019","unstructured":"Blot K, Duchateau L, Lescrauwaet B, Liyanage N, Ray D, Mirakhur B, et al. A patient-reported outcomes analysis of lanreotide in the treatment of NETs patients with carcinoid syndrome: evidence from the ELECT trial. Patient Relat. 2019;10:335\u201343.","journal-title":"Patient Relat"},{"issue":"9","key":"1071_CR29","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.4158\/EP151172.OR","volume":"22","author":"AI Vinik","year":"2016","unstructured":"Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA, * ESG. Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (elect): a randomized, double-blind placebo-controlled trial. Endocr Pract. 2016;22(9):1068\u201380.","journal-title":"Endocr Pract"},{"issue":"5","key":"1071_CR30","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.dld.2015.12.013","volume":"48","author":"P Ruszniewski","year":"2016","unstructured":"Ruszniewski P, Valle JW, Lombard-Bohas C, Cuthbertson DJ, Perros P, Holubec L, et al. Patient-reported outcomes with lanreotide Autogel\/depot for carcinoid syndrome: an international observational study. Dig Liver Dis. 2016;48(5):552\u20138.","journal-title":"Dig Liver Dis"},{"issue":"4","key":"1071_CR31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000082875","volume":"80","author":"P Ruszniewski","year":"2004","unstructured":"Ruszniewski P, Ish-Shalom S, Wymenga M, O\u2019Toole D, Arnold R, Tomassetti P, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology. 2004;80(4):244\u201351.","journal-title":"Neuroendocrinology"},{"issue":"1","key":"1071_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","volume":"35","author":"MH Kulke","year":"2017","unstructured":"Kulke MH, Horsch D, Caplin ME, Anthony LB, Bergsland E, Oberg K, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35(1):14\u201323.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1071_CR33","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.clinthera.2018.10.008","volume":"40","author":"D Cella","year":"2018","unstructured":"Cella D, Beaumont JL, Hudgens S, Marteau F, Feuilly M, Houchard A, et al. Relationship between symptoms and health-related quality-of-life benefits in patients with carcinoid syndrome: post hoc analyses from TELESTAR. Clin Ther. 2018;40(12):2006-20.e2.","journal-title":"Clin Ther"},{"issue":"4","key":"1071_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.clinthera.2016.03.002","volume":"38","author":"HL Gelhorn","year":"2016","unstructured":"Gelhorn HL, Kulke MH, O\u2019Dorisio T, Yang QM, Jackson J, Jackson S, et al. Patient-reported symptom experiences in patients with carcinoid syndrome after participation in a study of telotristat etiprate: a qualitative interview approach. Clin Ther. 2016;38(4):759\u201368.","journal-title":"Clin Ther"},{"issue":"1","key":"1071_CR35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s41687-019-0153-y","volume":"3","author":"S Hudgens","year":"2019","unstructured":"Hudgens S, Ramage J, Kulke M, Bergsland E, Anthony L, Caplin M, et al. Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. J Patient Rep Outcomes. 2019;3(1):64.","journal-title":"J Patient Rep Outcomes."},{"key":"1071_CR36","unstructured":"EORTC. Quality of Life of Cancer Patients EORTC QLQ-C30 questionnaire (version 3). 1995. https:\/\/qol.eortc.org\/questionnaire\/eortc-qlq-c30\/. Accessed 26 Dec 2020"},{"key":"1071_CR37","unstructured":"EORTC. EORTC QLQ-C30 Scoring Manual. 2011. https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/SCmanual.pdf. accessed 26 Dec 2020"},{"issue":"2","key":"1071_CR38","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/bjc.2012.560","volume":"108","author":"G Yadegarfar","year":"2013","unstructured":"Yadegarfar G, Friend L, Jones L, Plum LM, Ardill J, Taal B, et al. Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Br J Cancer. 2013;108(2):301\u201310.","journal-title":"Br J Cancer"},{"key":"1071_CR39","unstructured":"Cella D. functional assessment of cancer therapy\u2014general (FACT-G). 2007. https:\/\/www.facit.org\/measures\/FACT-G. Accessed 26 Dec 2020"},{"issue":"1","key":"1071_CR40","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12885-019-5459-x","volume":"19","author":"DM Halperin","year":"2019","unstructured":"Halperin DM, Huynh L, Beaumont JL, Cai B, Bhak RH, Narkhede S, et al. Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome. BMC Cancer. 2019;19(1):274.","journal-title":"BMC Cancer"},{"issue":"47","key":"1071_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013390","volume":"97","author":"DM Halperin","year":"2018","unstructured":"Halperin DM, Huynh L, Beaumont JL, Cai B, Totev T, Bhak RH, et al. Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: a survey study. Medicine (Baltimore). 2018;97(47): e13390.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"1071_CR42","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1530\/ERC-11-0367","volume":"19","author":"LK Kvols","year":"2012","unstructured":"Kvols LK, Oberg KE, O\u2019Dorisio TM, Mohideen P, de Herder WW, Arnold R, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer. 2012;19(5):657\u201366.","journal-title":"Endocr Relat Cancer"},{"issue":"273","key":"1071_CR43","first-page":"185","volume":"35","author":"SM Hunt","year":"1985","unstructured":"Hunt SM, McEwen J, McKenna SP. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract. 1985;35(273):185\u20138.","journal-title":"J R Coll Gen Pract"},{"issue":"4","key":"1071_CR44","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","volume":"88","author":"D O'Toole","year":"2000","unstructured":"O\u2019Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouche O, Catus F, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000;88(4):770\u20136.","journal-title":"Cancer"},{"issue":"11","key":"1071_CR45","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1016\/j.clinthera.2017.09.013","volume":"39","author":"L Anthony","year":"2017","unstructured":"Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, et al. Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clin Ther. 2017;39(11):2158\u201368.","journal-title":"Clin Ther"},{"issue":"1","key":"1071_CR46","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12955-018-1055-z","volume":"16","author":"A Ousmen","year":"2018","unstructured":"Ousmen A, Touraine C, Deliu N, Cottone F, Bonnetain F, Efficace F, et al. Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review. Health Qual Life Outcomes. 2018;16(1):228.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"1071_CR47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/M20-1392","volume":"174","author":"DJ Vanness","year":"2021","unstructured":"Vanness DJ, Lomas J, Ahn H. A health opportunity cost threshold for cost-effectiveness analysis in the United States. Ann Intern Med. 2021;174(1):25\u201332.","journal-title":"Ann Intern Med"},{"key":"1071_CR48","doi-asserted-by":"publisher","unstructured":"Cella William D, Arthur R, Nan S, Bryce R, Susan R, Dagmar Y, Rita A, Daniel B, Seung B, Karon C, Robert C, Darren D, James FD, Richard F, Elizabeth AG, Jin-Shei H, Paul L, Dennis P, Matthias R, Kevin R, Hays WR. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\u20132008. J Clin Epidemiol 2010;63(11) 1179\u201394. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.011","DOI":"10.1016\/j.jclinepi.2010.04.011"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01071-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-021-01071-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01071-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T07:47:29Z","timestamp":1634284049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-021-01071-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,11]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1071"],"URL":"https:\/\/doi.org\/10.1007\/s40273-021-01071-0","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,11]]},"assertion":[{"value":"18 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported in part by a grant from the National Cancer Institute (I-Wen Pan, James C. Yao, and Ya-Chen Tina Shih; R01 CA225647).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Daniel M. Halperin has received research funding from AAA, Lexicon, Incyte, Genentech, and Tarveda and has had consulting roles with AAA, Lexicon, Ipsen, and Curium. Ya-Chen Tina Shih has received consulting fees, travel, and accommodation for serving on a grants review panel for Pfizer Inc. and an advisory board for AstraZeneca. James C. Yao has had consulting roles with AAA, Chiasma, Crinetics, Ipsen, and Novartis. I-Wen Pan and Bumyang Kim have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Pan conceptualized the study framework, designed tables and figures, analyzed and interpreted study findings, and drafted the manuscript. Halperin and Kim contributed critical reviews of the manuscripts identified from search criteria, commented on the interpretation of the study findings, and drafted the manuscript. Shih and Yao aided in determining the appropriateness of articles included in the review along with interpreting the results and revising the manuscript draft. All authors discussed the results and study conclusions. All authors reviewed and approved the manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"The authors thank the clinical librarian, Yimin Geng, of the Research Medical Library at The University of Texas MD Anderson Cancer Center for searching for and providing a list of the relevant literature for this review. We acknowledge Gary Deyter in the Department of Health Services Research for editing the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgments"}}]}}